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health care professionals and health economists from the begin-
ning of MD development; and deﬁning MD to be evaluated in
priority, on which economic evaluation methods should be tested
before being applied to others.
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USE OF PHARMACOECONOMICS/HEALTH ECONOMIC TOOL
(PE/HE) IN LOCAL HEALTH CARE DECISION MAKING (DM)
Soto H1, Guzman S2, Reynoso N2, Cortes L3
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OBJCETIVE: To evaluate the basic knowledge level of DM
(General manager of the Hospital-GMH- and Chief of clinical
service-SCS-) about the application of PE/HE tool as inﬂuence
characteristics in decision make as well as main advantages and
obstacles. METHODS: A transversal survey was performing. In
a not related forum, DM was invited to complete a self-report
questionnaire about utilization of concepts of PE/HE in local
health care decision make. The main inclusion criteria were the
DM taken part in the process of evaluation inclusions of drugs
on the basic formulary. Descriptive and multivariate analysis test
were applied. RESULTS: A total of 139 questionnaires were
included for the analysis. Male 76.98%, the mean of (SD): age
48.28 (+6.35), time of labour experience 19.5 (+7.02). The
30.22% was SCS and 14.39% were GMH. The more important
characteristics for inclusions of drugs on the basic formulary are
efﬁcacy (82.73%) and safety and tolerability (76.94%). The
PE/HE was ﬁfth (64.03%). 44.60% had training in PE/HE
topics. Cost-beneﬁt was the concept mentioned more frequently
(75.54%). The 68.35% used PE/HE for inclusions of drugs on
the basic formulary. The probability of using PE/HE is 3.97 times
stolen high if DM has taken PE/HE course. The perception of
the group of the advantages de PE/HE help them to optimize the
resource (54.68%) and to give validation and realiable informa-
tion (7.91%). About the obstacle of use of PE/HE, DM men-
tioned the difﬁcult of access of the PE/HE (36.20%) and lack of
training (20.69%). A low percentage of participate wrote correct
the concepts of PE/HE. CONCLUSIONS: It is important to
strengthen the knowledge and utilization of the PE/HE tools in
Mexican DM.
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ANALYSIS OF QUALITY OF LIFE DATA FROM DIFFERENT
UTILITY INSTRUMENTS—AN EXAMPLE USING IMPUTATION
Fitzgerald P,Tilden D,Aristides M
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OBJECTIVES: Utilities are increasingly used to measure quality
of life (QoL) for health states, and a variety of instruments can
be used for this purpose. When QOL measures for different
groups are obtained using different instruments, comparing
summary statistics formally is difﬁcult and there is nothing
described in the methodology or applied literature. In this pre-
sentation we propose a relatively simple approach for compar-
ing QoL mean scores from EuroQoL and AqoL questionnaires
indirectly when this situation is encountered, which leads to a
result equivalent to that of a t-test. METHODS: Using an
example from a utility study for illustration, we describe a
method based on multiple imputation (MI), an approach com-
monly used to deal with missing data. From an estimate of the
correlation between the total mean scores, we describe how
simple linear regression can be used to obtain imputed values of
EuroQoL scores from AQoL scores. The multiple imputation
approach then offers simple techniques to obtain pooled esti-
mates of mean difference and variance on the EuroQoL scale.
RESULTS: We show how the resulting data can be used in a
simple way to generate a valid t-test statistic on the same QoL
scale. We then brieﬂy discuss the strengths and weaknesses of
this approach from the point of view of QoL measures as well
as methodology. CONCLUSIONS: The approach we present can
be used to compare data from different QoL instruments. We
summarise the circumstances under which such comparisons
would be valid, and also highlight situations when this approach
should not be used.
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DEVELOPMENT AND VALIDATION OF A DUTCH VERSION OF
THE LONDON HANDICAP SCALE
Groothuis-Oudshoorn CG1, Chorus AM2, Detmar SE2, Hosli EJ2,
Beekum W2,Verrips G2
1Roessingh Research and Development, Enschede,The Netherlands;
2TNO Quality of Life, Leiden,The Netherlands
OBJECTIVES: To describe the development and validation of a
Dutch version of the London Handicap Scale (DLHS). This ques-
tionnaire was based on the London Handicap Scale, a valid and
reliable utility instrument for measuring social participation in
adults. METHODS: The DLHS was tested in 803 adults with a
questionnaire consisting of the DLHS itself, the Impact on Par-
ticipation and Autonomy’ questionnaire (IPA), the Dutch version
of the EuroQol EQ-5D and questions concerning e.g. chronic
diseases, use of medical devices. The study population consisted
of patients with rheumatoid arthritis, cara/asthma, epilepsy,
larynchetomy and multiple sclerosis. RESULTS: Content valida-
tion, evaluated by relating the scores on the dimensions of the
DLHS and the number of chronic diseases was satisfactory. Con-
ceptual validation was shown by large (or some moderate,
almost large) correlations of predeﬁned pairs of the DLHS
dimensions with domains of the IPA. Correlations between the
DLHS sumscore and the IPA subscales were considerably larger
than corresponding correlations between the EQ-5D and the IPA
subscales, indicating a good concurrent validity of the DLHS.
The ability of the DLHS to discriminate between various sub-
groups of chronically ill persons ﬁve criteria was shown by cor-
relating the DLHS sumscore with ﬁve predeﬁned criteria.
CONCLUSIONS: Based on this evaluation the questionnaire
seems feasible and valid for assessing differences between differ-
ent subgroups of chronically ill or disabled persons in The
Netherlands.
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QUESTIONNAIRE FOR IRON OVERLOAD (IO) PATIENTS ON
CHELATION THERAPY (CT)
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OBJECTIVES: Desferal (DFO), the most common CT for IO,
requires infusions of 8–12 hours, 5–7 days per week. Oral for-
mulations are in development. Consequences of the high burden
of current chelation therapy with Desferal are poor treatment
adherence and satisfaction potentially leading to sub-optimal
clinical outcome. However, CT-speciﬁc satisfaction question-
naires have not been developed. METHODS: Five steps were
taken to develop the satisfaction questionnaire: literature review,
patient interviews, clinician interviews, item generation and
content validity testing. Three IO expert interviews and four
patient interview transcripts were reviewed to assess satisfaction
with DFO and reactions to a hypothetical oral CT. Items were
developed based on these steps and tested in nine patients
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(US/UK). Patients also provided their opinions of current CT
with DFO to ensure that no major concepts were omitted.
RESULTS: The literature review revealed no IO or CT speciﬁc
questionnaires, though several articles recounted DFO’s incon-
venience and impact. Patient and clinician interviews suggested
that patients were most concerned about the efﬁcacy, side effects,
convenience and costs of any new IO treatment. Satisfaction with
DFO was low, primarily due to local site reactions, inconve-
nience, and the constraining nature of the therapies. Presented
with a hypothetical oral CT, patients unanimously preferred oral
CT. A 40-item questionnaire was developed that assessed
patients’ expectations of and satisfaction with attributes identi-
ﬁed as important including efﬁcacy, safety, convenience and side
effects, along with costs, overall satisfaction, treatment impact,
patient compliance, and preferences. Results from the content
validity testing resulted in additions to the instructions and the
rewording of six items. CONCLUSIONS: To accurately assess
satisfaction, patient input should be obtained. In the absence of
real-life experience with the proposed therapy, unbiased hypo-
thetical product proﬁles were used to elicit the dimensions
important to patients, and this is consistent with established
methods. Psychometric validation is currently underway.
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LIVING SCALE IN ASIAN OLDER ADULTS
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OBJECTIVE: Item response bias (also called differential item
functioning, DIF) in Instrumental Activities of Daily Living
(IADL) occurs when members of different groups possessing the
same disability level do not have the same probability of
responding positively for a given item(s). This study aimed to
identify the extent of DIF by gender, age, ethnicity and demen-
tia groups in IADL estimates in Asian (Chinese, Malay and
Indian) elderly subjects. METHODS: Data of the 2003 National
Mental Health Survey were analyzed from 1072 non-institu-
tionalized elderly subjects using multiple indicator–multiple
cause latent variable (MIMIC) modeling. RESULTS: Given the
same functional level, older elderly were less likely to report
receiving help with preparing meals; men were more likely to
report receiving help with preparing meals, doing laundry, and
taking medication; Malays were more likely to report receiving
help with using telephone; and demented elderly were more
likely to report receiving help with using telephone, managing
money, taking medications, and “getting around”. The impact
of DIF on group differences was highest for gender (54.0%), eth-
nicity (42.9%), dementia (14.7%) and age (2.4%). CONCLU-
SION: Item-response bias in IADL estimates by gender, age,
ethnicity and dementia should be considered in direct compar-
isons of disability status among population groups.
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COST ANALYSIS OF MANAGEMENT STRATEGIES FOR
CLOSED AND OPEN GRADE I TIBIAL SHAFT FRACTURES
Busse JW1, Bhandari M1, Sprague S1, Johnson-Masotti AP2, Gafni A2
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OBJECTIVES: To conduct a cost analysis of current competing
strategies for the management of patients with closed and open
grade I tibial shaft fractures, from both a governmental and soci-
etal perspective. METHODS: Our cost analysis was performed
for four competing treatment strategies for management of
closed or grade I open tibial fractures: 1). casting alone; 2).
casting with therapeutic ultrasound; 3). operative treatment with
non-reamed intramedullary nailing; and 4). operative treatment
with reamed intramedullary nailing. The time to radiographic
fracture union was used as the measure of effectiveness. Given
the multiple clinical alternatives, each with the potential to result
in a number of outcomes, a decision tree was used to perform
all cost analyses. Sensitivity analysis was conducted through
Monte Carlo simulations. RESULTS: From a governmental per-
spective the mean associated costs were USD $3365 (standard
deviation [SD] ± 1425) for operative management by reamed
intramedullary nailing, $5041 (SD ± 1363) for operative man-
agement by non-reamed intramedullary nailing, $5017 (SD ±
1370) for casting, and $5312 (SD ± 1474) for casting with 
therapeutic ultrasound. From a societal perspective the mean
associated costs were ($12,449; SD ± 4894) for reamed
intramedullary nailing, ($13,266; SD ± 3692) for casting with
therapeutic ultrasound, ($15,571; SD ± 4293) for operative man-
agement by non-reamed intramedullary nailing, and ($17,343;
SD ± 4784) for casting alone. CONCLUSIONS: Our preliminary
cost analysis suggests that, from both a governmental and soci-
etal perspective, reamed intramedullary nailing is the treatment
of choice for closed and open grade I tibial shaft fractures.
However, there is evidence that, from a societal perspective,
treatment of low energy tibial fractures with therapeutic 
ultrasound and casting may also be an economically-sound 
intervention.
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COST-EFFECTIVENESS ANALYSIS OF ACLASTA IN PAGET’S
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OBJECTIVES: To assess, in the Belgian setting, the costs, efﬁ-
cacy, and cost-effectiveness of zoledronic acid 5mg (Aclasta)
versus conventional therapies (tiludronate (Skelid), pamidronate
(Aredia), and risedronate (Actonel)) in the management of
patients with Paget’s disease of bone (PDB). METHODS: Based
on efﬁcacy data from pivotal zoledronic acid 5mg clinical trials
and the literature, a decision tree model was developed to reﬂect
the treatment path with the different drugs compared. This
model takes into account four health states and links efﬁcacy
data to Belgian resource use data. It covers a 2-year time horizon.
The outcome measure chosen is time in response, deﬁned as time
in which serum alkaline phosphatase is controlled. Direct
medical costs, from the perspective of the health care payer
(INAMI/RIZIV) were considered and discounting was applied in
the second year. The consumption of medical resources (drug
treatments including administration costs, laboratory tests, and
physician consultations) was assessed via expert opinion.
RESULTS: Over two years, the expected average numbers of
months in response for patients treated with zoledronic acid 5
mg and conventional treatments (tiludronate, pamidronate, and
risedronate) are: 20.9 months; 11.1 months; 9.3 months; and
16.2 months, respectively. Over this period, the expected average
costs for patients treated with zoledronic acid 5mg and conven-
tional treatments (tiludronate, pamidronate, and risedronate)
are: €686; €1525; €1245; and €793, respectively. Hence, zole-
dronic acid 5mg dominates all the other bisphosphonates com-
pared, i.e. zoledronic acid 5mg is less costly and more effective.
